Format

Send to

Choose Destination
See comment in PubMed Commons below
Am J Med Sci. 2012 Jul;344(1):52-8. doi: 10.1097/MAJ.0b013e318239c4ee.

Survivin knockdown enhances gastric cancer cell sensitivity to radiation and chemotherapy in vitro and in nude mice.

Author information

  • 1Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, China.

Abstract

INTRODUCTION:

The aim is to assess the effect of survivin knockdown on the radio- and chemosensitivity of gastric cancer cells in vitro and in nude mice.

METHODS:

Survivin messenger RNA and protein were detected by semiquantitative reverse transcription-polymerase chain reaction and Western blot. Survivin and control small hairpin RNA (shRNA) expression constructed vectors were stably transfected into gastric cancer SGC7901 cells. The cells were in turn subjected to irradiation, cisplatin or fluorouracil (5-FU) treatment for colony formation, methyl-thiazolyl-tetrazolium cell viability and flow cytometry assays in vitro. An in vivo nude mouse xenograft assay was performed to assess the effects of Survivin knockdown on regulation of the sensitivity of SGC7901 cells to irradiation, cisplatin or 5-FU treatment.

RESULTS:

Survivin shRNA markedly inhibited levels of survivin messenger RNA and protein in SGC7901 cells and significantly increased sensitivity of the tumor cells to radiation treatment, ie, the mean lethal and quasi-threshold doses in survivin shRNA-transfected cells were significantly lower than that of the negative control shRNA-transfected and parental cells. The same is true for cisplatin- and 5-FU-treated tumor cells, ie, colony formation and cell viability of the survivin-knocked down SGC7901 cells were reduced, while apoptosis was induced compared with the control cells. Furthermore, the xenograft assay showed survivin knockdown in SGC7901 cells suppressed tumor formation and growth compared with the controls.

CONCLUSIONS:

Knockdown of survivin expression enhanced sensitivity of gastric cancer cells to radiation, cisplatin and 5-FU treatment in vitro and in nude mice. These results demonstrate that clinical trails are warranted of survivin shRNA as an adjuvant therapy for gastric cancer patients.

PMID:
22261621
DOI:
10.1097/MAJ.0b013e318239c4ee
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center